Abstract
Introduction
The Amyloid/Tau/Neurodegeneration (ATN) framework was proposed to identify the preclinical biological state of Alzheimer’s disease (AD). We investigated whether ATN phenotype can be predicted using routinely collected research cohort data.
Methods
927 EPAD LCS cohort participants free of dementia or Mild Cognitive Impairment were separated into 5 ATN categories. We used machine learning (ML) methods to identify a set of significant features separating each neurodegeneration-related group from controls (A-T-(N)-). Random Forest and linear-kernel SVM with stratified 5-fold cross validations were used to optimize model whose performance was then tested in the ADNI database.
Results
Our optimal results outperformed ATN cross-validated logistic regression models by between 2.2% and 8.3%. The optimal feature sets were not consistent across the 4 models with the AD pathologic change vs controls set differing the most from the rest. Because of that we have identified a subset of 10 features that yield results very close or identical to the optimal.
Discussion
Our study demonstrates the gains offered by ML in generating ATN risk prediction over logistic regression models among pre-dementia individuals.
Funder
Alzheimer's Disease Neuroimaging Initiative
DOD ADNI
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
AbbVie
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
Biogen
Bristol-Myers Squibb Company
CereSpir, Inc.
Cogstate
Eisai Inc.
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun
F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
Fujirebio
GE Healthcare
IXICO Ltd.
Janssen Alzheimer Immunotherapy Research & Development, LLC.
Johnson & Johnson Pharmaceutical Research & Development LLC.
Lumosity
Lundbeck
Merck & Co., Inc.
Meso Scale Diagnostics, LLC.
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Piramal Imaging
Servier
Takeda Pharmaceutical Company
Transition Therapeutics
Canadian Institutes of Health Research
Foundation for the National Institutes of Health
Northern California Institute for Research and Education
Alzheimer's Therapeutic Research Institute at the University of Southern California
Publisher
Public Library of Science (PLoS)